Top

Published in:

01-10-2006 | Original Paper

Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas

Authors: Jorge H. Mukdsi, Ana Louis De Paul, Juan P. Petiti, Silvina Gutiérrez, Agustín Aoki, Alicia I. Torres

Published in: Acta Neuropathologica | Issue 4/2006

Abstract

Fibroblast growth factor-2 (FGF-2) synthesized in the pituitary is involved in the formation and progression of pituitary tumors. The aim of this study was to analyze the pattern expression of two FGF-2 isoforms at different subcellular levels and to determine its correlation with prolactinoma development. Estrogen administration to male rats for 7, 20, and 60 days generated pituitary tumors, with lactotrophs being the prevalent cell type. Ultrastructural immunolabeling showed FGF-2 in the cytosolic and nuclear compartments of somatotrophs, lactotrophs and gonadotrophs, as well as in folliculo-stellate cells of normal rats. Estrogen stimulation increased FGF-2 immunoreactivity in various tumors and enhanced the expression of two FGF-2 isoforms, 18 and 22 kDa, as quantified by western blot. The 18 kDa isoform observed in cytosol extracts reached the highest levels after 60 days of hormonal stimulation and this was related to lactotroph proliferation. However, the 22 kDa FGF-2 isoform was only detected in the nuclear compartment and achieved the maximum expression at 7 days of estrogen treatment, without any correlation with lactotroph proliferation. These results suggest that the 18 kDa FGF-2 may play a role in the modulation of lactotroph proliferation in prolactinomas induced by estrogen. The overproduction of both FGF-2 isoforms appears to be implicated in autocrine–paracrine–intracrine mitogenic loops; this FGF-2 activity could lead to uncontrolled cell growth, angiogenesis, and tumor formation.

Akashi T, Minami J, Ishige Y, Eishi Y, Takizawa T, Koike M, Yanagishita M (2005) Basement membrane matrix modifies cytokine interactions between lung cancer cells and fibroblasts. Pathobiology 72:250–259PubMedCrossRef

Amano O, Yoshitake Y, Nishikawa K, Iseki S (1993) Immunocytochemical localization of basic fibroblast growth factor in the rat pituitary gland. Arch Histol Cytol 56:269–276PubMed

Arnaud E, Touriol C, Boutonnet C, Gensac MC, Vagner S, Prats H, Prats AC (1999) A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol 19:505–514PubMed

Asa S, Ezzat S (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2:1–12CrossRef

Backhaus R, Zehe C, Wegehingel S, Kehlenbach A, Schwappach B, Nickel W (2004) Unconventional protein secretion: membrane translocation of FGF-2 does not require protein unfolding. J Cell Sci 117:1727–1736PubMedCrossRef

Baird A, Esch F, Mormede P, Ueno N, Ling N, Bohlen P, Ying SY, Wehrenberg WB, Guillemin R (1986) Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. Recent Prog Horm Res 42:143–205PubMed

Bikfalvi A, Klein S, Pintucci G, Rifkin D (1997) Biological roles of fibroblast growth factor 2. Endocr Rev 18:26–45PubMedCrossRef

Bugler B, Amalric F, Prats H (1991) Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 11:573–577PubMed

Chaturvedi K, Sarkar DK (2004) Involvement of protein kinase C-dependent mitogen-activated protein kinase p44/42 signaling pathway for cross-talk between estradiol and transforming growth factor-beta3 in increasing basic fibroblast growth factor in folliculostellate cells. Endocrinology 145:706–715PubMedCrossRef

10.

Chaturvedi K, Sarkar DK (2005) Mediation of basic fibroblast growth factor-induced lactotropic cell proliferation by Src-Ras-mitogen-activated protein kinase p44/42 signaling. Endocrinology 146:1948–1955PubMedCrossRef

11.

Chen CH, Poucher SM, Lu J, Henry PD (2004) Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2:33–43PubMedCrossRef

12.

Delrieu I (2000) The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett 468:6–10PubMedCrossRef

13.

Ezzat S (2001) The role of hormone, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 11:356–370PubMedCrossRef

14.

Florkiewicz RZ, Sommer A (1989) Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci USA 86:3978–3981PubMedCrossRef

15.

Fukui S, Otani N, Nawashiro H, Yano N, Miyazaqwa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Suzuki T, Shima K (2002) Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol 57:221–229PubMedCrossRef

16.

Fukui S, Otani N, Nawashiro H, Yano N, Miyazaqwa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Suzuki T, Shima K (2003) Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. Cancer 97:3061–3067PubMedCrossRef

17.

Garmy-Susini B, Delmas E, Gourdy P, Zhou M, Bossard C, Bugler B, Bayard F, Krust A, Prats AC, Doetschman T, Prats H, Arnal JF (2004) Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation. Circ Res 94:1301–1309PubMedCrossRef

18.

Heaney A, Horwitz G, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumour transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321PubMedCrossRef

19.

Itoh J, Serizawa A, Kawai K, Ishii Y, Teramoto A, Osamura Yoshiyuki R (2003) Vascular networks and endothelial cells in rat experimental pituitary glands and in the human pituitary adenomas. Microsc Res Tech 60:231–235PubMedCrossRef

20.

Kang HB, Kim JS, Kwon HJ, Nam KH, Youn HS, Sok DE, Lee Y (2005) Basic fibroblast growth factor activates ERK and induces c-fos in human embryonic stem cell line MizhES1. Stem Cells Dev 14:395–401PubMedCrossRef

21.

Keresztes M, Boonstra J (1999) Importance of growth factors into the nucleus. J Cell Biol 145:421–424PubMedCrossRef

22.

López J, Fernández I, Palacios D, Castillo A, Tolón R, Aranda A, Karin M (2000) Differentiation of lactotrope precursor GHFT cells in response to fibroblast growth factor-2. J Biol Chem 275:21653–21660CrossRef

23.

Madan AK, Kramer B (2005) Immunolocalization of fibroblast growth factor-2 (FGF-2) in the developing root and supporting structures of the murine tooth. J Mol Histol 36:171–178PubMedCrossRef

24.

Maher PA (1996) Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 134:529–536PubMedCrossRef

25.

Maldonado C, Aoki A (1986) Improvement of prolactin immuno-labeling in osmium-fixed acrylic-embedded pituitary gland. Basic Appl Histochem 30:301–305PubMed

26.

Marin F, Boya J (1995) Immunocytochemical localization of basic fibroblast growth factor in the human pituitary gland. Neuroendocrinology 62:523–529PubMed

27.

Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603–1618PubMedCrossRef

28.

Mignatti P, Morimoto T, Rifkin DB (1991) Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sci USA 88:11007–11111PubMedCrossRef

29.

Mukdsi JH, De Paul AL, Munoz S, Aoki A, Torres AI (2004) Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen. Histochem Cell Biol 121:453–462PubMedCrossRef

30.

Mukdsi JH, De Paul AL, Gutiérrez S, Roth F, Aoki A, Torres AI (2006) Subcellular localisation of VEGF in different pituitary cells. Changes of its expression in estrogen induced prolactinomas. J Mol Histol 36:447–454CrossRef

31.

Nickel W (2003) The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 270:2109–2119PubMedCrossRef

32.

Okada-Ban M, Thiery JP, Jouanneau J (2000) Fibroblast growth factor-2. Int J Biochem Cell Biol 32:263–267PubMedCrossRef

33.

Oomizu S, Chaturvedi K, Sarkada DK (2004) Folliculostellate cells determine the susceptibility of lactotropes to estradiol’s mitogenic action. Endocrinology 145:1473–1480PubMedCrossRef

34.

Piroli G, Torres AI, Pietranera L, Grillo C, Ferrini M, Lux-Santos V, Aoki A, De Nicola A (2000) Sexual dimorphism in diethylstilbestrol-induced prolactin pituitary tumors in F344 rats. Neuroendocrinology 72:80–90PubMedCrossRef

35.

Quarto N, Fong KD, Longaker MT (2005) Gene profiling of cells expressing different FGF-2 forms. Gene 56:49–68CrossRef

36.

Re RN (2003) The intracrine hypothesis and intracellular peptide hormone action. Bioessays 25:401–409PubMedCrossRef

37.

Re RN (2004) A proposal regarding the biology of memory: participation of intracrine peptide networks. Med Hypotheses 63:887–894PubMedCrossRef

38.

Renner U, Paez-Pereda M, Arzt E, Stalla GK (2004) Growth factors and cytokines: function and molecular regulation in pituitary adenomas. Front Horm Res 32:96–109PubMed

39.

Schechter JE (1992) Is cellular disruption the mechanism of release of basic fibroblast growth factor from anterior pituitary gonadotropes? Tissue Cell 24:791–802PubMedCrossRef

40.

Sugawara A, Yen PM, Darling DS, Chin W (1993) Characterization and tissue expression of multiple triiodothyronine receptor-auxiliary proteins and their relationship to the retinoid X-receptor. Endocrinology 133:965–971PubMedCrossRef

41.

Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24:600–632PubMedCrossRef

42.

Yamada S, Takada K (2003) Angiogenesis in pituitary adenomas. Microsc Res Tech 60:236–243PubMedCrossRef

43.

Zhan X, Hu X, Friedman S, Maciag T (1992) Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH 3T3 cells. Biochem Biophys Res Commun 188:982–991PubMedCrossRef

Title: Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas
Authors: Jorge H. Mukdsi
Ana Louis De Paul
Juan P. Petiti
Silvina Gutiérrez
Agustín Aoki
Alicia I. Torres
Publication date: 01-10-2006
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 4/2006
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-006-0101-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2006

No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer’s disease brain

Optic nerve axonal pathology is related to abnormal visual evoked responses in AIDS

MM2-thalamic-type sporadic Creutzfeldt-Jakob disease with widespread neocortical pathology

The fate of Nissl-stained dark neurons following traumatic brain injury in rats: difference between neocortex and hippocampus regarding survival rate

Kurt Jellinger Prize 2007 for outstanding scientific writing in neuropathology

The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison